PXL/HO/Cir-050/2020-21 Date: 26.07.2020
Sub: Anti- COVID drugs offered by Russian Industries to Indian companies
You may kindly be aware, Russia has domestically developed a few drugs and registered a number of foreign drugs for treatment of COVID- 19. Out of these drugs, Russian Ministry of Health & its industry has offered to supply three indigenously manufactured anti- COVID drugs which are showing positive results in Russia to Indian companies. The details of the drugs shared by the Russian Health ministry is appended below:
(i)Favipiravir (Trade name: Avifavir):
Manufactured by Research Institute of Chemical Diversity, Russia. Contact: Yuri Nikolaevich Krasnenkov, e-mail: firstname.lastname@example.org, Tel.: +7-903-611-93-51 or Alexander Azarov, e-mail: email@example.com, Tel: +7-962-982-03-02.
(ii) Olokizumab (Trade name: Artlegia):
Holder of registration certificate: JSC R-Pharm Artlegia (olokizumab) is a humanized monoclonal antibody that directly blocks the inflammatory mediator Interleukin-6 (IL-6).
Produced by R-Pharm, Russia. Contact: Tel: +7 (495) 956-79-37; +7(495) 956-79-38, e-mail: firstname.lastname@example.org.
(iii) Levilimab (Trade name: Ilsira):
The drug is deemed to be recommended for patients with the so-called ‘cytokine storm’.
Produced by Dmitry Alekseevich Pasechnik, Commercial Director for International Markets, Tel.: +7-964-333-66-61, e-mail: email@example.com.
We are glad to share this information and the members having substantive commercial interest, are requested to approach the contacts provided for each drug.
Note: Import of any drug into India needs to be complied as per the provisions of the Drugs & Cosmetics Act, 1940 & Rules 1945.